Table 2.
Nasopharyngeal Swab SARS-CoV-2 RNA by Visit and Treatment Arm
| BMS mAbs n=105 | Placebo n=106 | Analysis Results Risk Ratio [95%CI] | ||
|---|---|---|---|---|
| Day 0 | n <LLoQ ≥LLoQ |
100 34 (34.0%) 66 (66.0%) |
99 31 (31.3%) 68 (68.7%) |
|
| Day 3 | n <LLoQ ≥LLoQ |
89 42 (47.2%) 47 (52.8%) |
93 44 (47.3%) 49 (52.7%) |
1.03 [0.80, 1.32] Ref |
| Day 7 | n <LLoQ ≥LLoQ |
90 71 (78.9%) 19 (21.1%) |
88 64 (72.7%) 24 (27.3%) |
1.04 [0.94, 1.15] Ref |
| Day 14 | n <LLoQ ≥LLoQ |
90 82 (91.1%) 8 (8.9%) |
91 85 (93.4%) 6 (6.6%) |
1.00 [0.90, 1.12] Ref |
| Overall | P=0.71a |
BMS mAbs, subcutaneously administered BMS-986414 (C135-LS) 200 mg plus BMS-986413 (C144-LS) 200 mg; LLoQ, lower limit of quantification of assay; NP, nasopharyngeal; CI, confidence interval Risk Ratio calculated as BMS mAbs versus placebo. Risk Ratio and 95% CI estimated from log-binomial models fitted using generalized estimating equations with an independent working correlation structure and robust standard errors.
a
A joint test or randomized time points were assessed using a 2-sided Wald test.